Jason Gerberry
Stock Analyst at B of A Securities
(4.34)
# 350
Out of 5,127 analysts
163
Total ratings
62.18%
Success rate
12.86%
Average return
Main Sectors:
Stocks Rated by Jason Gerberry
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PFE Pfizer | Maintains: Neutral | $29 → $28 | $27.22 | +2.87% | 5 | Dec 15, 2025 | |
| ARWR Arrowhead Pharmaceuticals | Maintains: Buy | $62 → $81 | $64.52 | +25.54% | 4 | Dec 9, 2025 | |
| IONS Ionis Pharmaceuticals | Maintains: Buy | $86 → $97 | $86.50 | +12.14% | 7 | Dec 9, 2025 | |
| TEVA Teva Pharmaceutical Industries | Maintains: Buy | $29 → $32 | $34.69 | -7.75% | 15 | Dec 9, 2025 | |
| JAZZ Jazz Pharmaceuticals | Maintains: Buy | $230 → $247 | $165.50 | +49.24% | 6 | Nov 18, 2025 | |
| OCS Oculis Holding AG | Maintains: Buy | $30 → $29 | $28.48 | +1.83% | 4 | Nov 13, 2025 | |
| AMPH Amphastar Pharmaceuticals | Maintains: Neutral | $28 → $32 | $29.26 | +9.38% | 2 | Aug 26, 2025 | |
| IMVT Immunovant | Maintains: Buy | $33 → $30 | $27.05 | +10.91% | 6 | Aug 12, 2025 | |
| BHVN Biohaven | Maintains: Buy | $50 → $49 | $11.60 | +322.41% | 2 | Aug 12, 2025 | |
| AXSM Axsome Therapeutics | Maintains: Buy | $173 → $176 | $182.55 | -3.59% | 6 | Aug 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $3 → $1 | $1.87 | -46.52% | 4 | Jun 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $25 → $23 | $43.04 | -46.56% | 2 | Jun 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $45 → $46 | $43.90 | +4.78% | 3 | Jun 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $157 → $137 | $56.15 | +143.99% | 9 | Apr 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underperform | $11 → $10 | $14.58 | -31.41% | 3 | Feb 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $30 | $24.44 | +22.75% | 2 | Jan 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $84 → $100 | $68.10 | +46.84% | 5 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $20 → $24 | $8.92 | +169.06% | 1 | Sep 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $41 → $31 | $33.36 | -7.07% | 6 | Apr 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $600 → $550 | $1.82 | +30,119.78% | 3 | Mar 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $27 → $29 | $34.91 | -16.93% | 9 | Jan 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $52 → $56 | $41.42 | +35.20% | 2 | Jan 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $30 | $37.27 | -19.51% | 2 | Jan 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $450 → $500 | $1,058.18 | -52.75% | 15 | May 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $9 | $1.69 | +432.54% | 1 | Dec 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $37 → $25 | $8.21 | +204.51% | 3 | Oct 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $45 → $5 | $1.50 | +233.33% | 2 | Dec 2, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $27 | $5.88 | +359.18% | 4 | Mar 24, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $20 | $2.14 | +834.58% | 1 | Jul 16, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $170 → $100 | $6.91 | +1,347.18% | 1 | Jul 15, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Neutral | $95 | $223.43 | -57.48% | 10 | May 18, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Buy | $60 | $61.99 | -3.21% | 7 | Oct 17, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Neutral | $90 | $121.93 | -26.19% | 11 | Oct 17, 2019 |
Pfizer
Dec 15, 2025
Maintains: Neutral
Price Target: $29 → $28
Current: $27.22
Upside: +2.87%
Arrowhead Pharmaceuticals
Dec 9, 2025
Maintains: Buy
Price Target: $62 → $81
Current: $64.52
Upside: +25.54%
Ionis Pharmaceuticals
Dec 9, 2025
Maintains: Buy
Price Target: $86 → $97
Current: $86.50
Upside: +12.14%
Teva Pharmaceutical Industries
Dec 9, 2025
Maintains: Buy
Price Target: $29 → $32
Current: $34.69
Upside: -7.75%
Jazz Pharmaceuticals
Nov 18, 2025
Maintains: Buy
Price Target: $230 → $247
Current: $165.50
Upside: +49.24%
Oculis Holding AG
Nov 13, 2025
Maintains: Buy
Price Target: $30 → $29
Current: $28.48
Upside: +1.83%
Amphastar Pharmaceuticals
Aug 26, 2025
Maintains: Neutral
Price Target: $28 → $32
Current: $29.26
Upside: +9.38%
Immunovant
Aug 12, 2025
Maintains: Buy
Price Target: $33 → $30
Current: $27.05
Upside: +10.91%
Biohaven
Aug 12, 2025
Maintains: Buy
Price Target: $50 → $49
Current: $11.60
Upside: +322.41%
Axsome Therapeutics
Aug 5, 2025
Maintains: Buy
Price Target: $173 → $176
Current: $182.55
Upside: -3.59%
Jun 30, 2025
Downgrades: Underperform
Price Target: $3 → $1
Current: $1.87
Upside: -46.52%
Jun 11, 2025
Maintains: Buy
Price Target: $25 → $23
Current: $43.04
Upside: -46.56%
Jun 5, 2025
Maintains: Neutral
Price Target: $45 → $46
Current: $43.90
Upside: +4.78%
Apr 1, 2025
Maintains: Buy
Price Target: $157 → $137
Current: $56.15
Upside: +143.99%
Feb 28, 2025
Maintains: Underperform
Price Target: $11 → $10
Current: $14.58
Upside: -31.41%
Jan 9, 2025
Reiterates: Buy
Price Target: $30
Current: $24.44
Upside: +22.75%
Nov 6, 2024
Maintains: Buy
Price Target: $84 → $100
Current: $68.10
Upside: +46.84%
Sep 10, 2024
Maintains: Buy
Price Target: $20 → $24
Current: $8.92
Upside: +169.06%
Apr 1, 2024
Downgrades: Underperform
Price Target: $41 → $31
Current: $33.36
Upside: -7.07%
Mar 25, 2024
Maintains: Buy
Price Target: $600 → $550
Current: $1.82
Upside: +30,119.78%
Jan 2, 2024
Maintains: Neutral
Price Target: $27 → $29
Current: $34.91
Upside: -16.93%
Jan 2, 2024
Maintains: Buy
Price Target: $52 → $56
Current: $41.42
Upside: +35.20%
Jan 2, 2024
Downgrades: Underperform
Price Target: $30
Current: $37.27
Upside: -19.51%
May 24, 2023
Maintains: Buy
Price Target: $450 → $500
Current: $1,058.18
Upside: -52.75%
Dec 12, 2022
Downgrades: Underperform
Price Target: $9
Current: $1.69
Upside: +432.54%
Oct 14, 2022
Downgrades: Underperform
Price Target: $37 → $25
Current: $8.21
Upside: +204.51%
Dec 2, 2021
Downgrades: Underperform
Price Target: $45 → $5
Current: $1.50
Upside: +233.33%
Mar 24, 2021
Downgrades: Underperform
Price Target: $27
Current: $5.88
Upside: +359.18%
Jul 16, 2020
Initiates: Neutral
Price Target: $20
Current: $2.14
Upside: +834.58%
Jul 15, 2020
Downgrades: Neutral
Price Target: $170 → $100
Current: $6.91
Upside: +1,347.18%
May 18, 2020
Reinstates: Neutral
Price Target: $95
Current: $223.43
Upside: -57.48%
Oct 17, 2019
Reinstates: Buy
Price Target: $60
Current: $61.99
Upside: -3.21%
Oct 17, 2019
Reinstates: Neutral
Price Target: $90
Current: $121.93
Upside: -26.19%